Aslan Fred 4

What Happened

• Fred Aslan, President, CEO and Director of Artiva Biotherapeutics (ARTV), received a restricted stock unit (RSU) award of 366,850 shares on 2026-02-15 under the company's equity plan. Simultaneously, 14,600 shares were withheld by the company to satisfy income tax withholding obligations at $4.00/share (total withheld value $58,400).
• This is a compensation grant (award), not an open-market purchase or sale; the share withholding is a routine tax-related disposition.

Key Details

• Transaction date: 2026-02-15; Form 4 filed 2026-02-18 (appears timely).
• Grant: 366,850 RSUs acquired at $0.00 (F1: awarded under the 2024 Equity Incentive Plan).
• Withholding/Disposition: 14,600 shares disposed at $4.00 each for tax withholding, value $58,400 (F2: shares withheld to satisfy income tax obligations).
• Net shares delivered to insider after withholding: 352,250 RSUs (366,850 granted minus 14,600 withheld).
• Shares owned after the transaction: not specified in the provided filing.

Context

• RSU grants are common executive compensation; withholding of shares to cover taxes is routine and does not necessarily indicate a change in the insider’s market view.
• This report reflects an award (A) and a tax-withholding disposition (F); it is not a market sale (S) or a purchase (P).